ストックスクリーナーアプリを入手
31.06
1.77%
0.54
前日終値:
$30.52
開ける：
$30.52
24時間の取引高:
3.37M
Relative Volume:
0.82
時価総額：
$5.06B
収益：
$56.99M
当期純損益:
$-107.23M
株価収益率:
-37.88
EPS:
-0.8199
ネットキャッシュフロー:
$-142.55M
1週間 パフォーマンス:
+5.43%
1か月 パフォーマンス:
+8.30%
6か月 パフォーマンス:
+164.34%
1年 パフォーマンス:
+408.35%
1日の値動き範囲:
$28.91
$31.48
1週間の範囲:
$28.91
$32.17
52週間の値動き範囲:
$5.595
$34.39
Tango Therapeutics Inc Stock (TNGX) Company Profile
Compare TNGX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
31.06 | 5.06B | 56.99M | -107.23M | -142.55M | -0.8199 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-02 | 開始されました | Canaccord Genuity | Buy |
| 2026-02-23 | 開始されました | Mizuho | Outperform |
| 2025-11-18 | 開始されました | Wolfe Research | Peer Perform |
| 2025-08-19 | 開始されました | Piper Sandler | Overweight |
| 2024-07-17 | 開始されました | Jefferies | Buy |
| 2024-04-04 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-02-12 | 開始されました | Piper Sandler | Overweight |
| 2023-12-08 | 開始されました | B. Riley Securities | Buy |
| 2022-10-20 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Tango Therapeutics Inc (TNGX) 最新ニュース
Top Hyperliquid Strategies (PURR) Competitors 2026 - MarketBeat
Does Tango Therapeutics' (TNGX) Russell Growth Shift Reveal Its True Biotech Identity to Institutions? - simplywall.st
TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside - Stocktwits
Tango Therapeutics president Crystal Adam sells $798,908 in stock By Investing.com - Investing.com South Africa
Form 4 Tango Therapeutics Inc For: 2 July By Investing.com - Investing.com India
Tango Therapeutics president Crystal Adam sells $798,908 in stock - Investing.com
Tango Therapeutics (TNGX) R&D president exercises options and sells 27,000 shares - Stock Titan
Price to book forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView
Tango Therapeutics Rides a New Precision Oncology Trend in 2026 - Yahoo Finance
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026? - Yahoo Finance
TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts - Yahoo Finance
TNGX Q1 2026 Earnings: Net Loss Slightly Misses Estimates as Pre-Revenue Biotech Advances PipelineHigh Growth Earnings - dars.gov.et
TNGX Maintained by Canaccord Genuity -- Price Target Raised to $46 - GuruFocus
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 2500 Growth Benchmark - marketscreener.com
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 2000 Growth Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM:TNGX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 3000E Growth Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell 3000E Index - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell Microcap Index - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell 2500 Value Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM:TNGX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell 3000E Value Benchmark - marketscreener.com
Enterprise value to revenue forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView
Enterprise value to EBITDA forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView
Jefferies Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $60 - Moomoo
TNGX Upgraded by Jefferies -- Price Target Raised to $60 - GuruFocus
Jefferies Upgrades Tango Therapeutics to Buy From Hold, Price Target Is $27 - Moomoo
Tango Therapeutics Inc (TNGX) Institutional Confidence - TradingKey
Tango Therapeutics, Inc. Actuals & Estimates (NASDAQ:TNGX) - TradingView
Enterprise value to EBIT forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView
Jefferies upgrades Tango Therapeutics stock rating on cancer trial data By Investing.com - Investing.com Nigeria
Jefferies Upgrades Tango Therapeutics(TNGX.US) to Buy Rating, Raises Target Price to $60 - Moomoo
Jefferies upgrades Tango Therapeutics stock rating on cancer trial data - Investing.com
TNGX Forecast — Price Target — Prediction for 2027 - TradingView
Why is Tango Therapeutics stock surging today? By Investing.com - Investing.com Nigeria
Price to sales forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView
Form 8K Tango Therapeutics Inc For: 23 June By Investing.com - Investing.com Australia
Form 4 Tango Therapeutics Inc For: 23 June By Investing.com - Investing.com South Africa
Director at Tango Therapeutics (TNGX) receives RSUs and stock options - Stock Titan
New Tango Therapeutics (TNGX) director Robert Azelby files initial Form 3 - Stock Titan
Robert Azelby appointed to Tango Therapeutics board, joins Compensation and NCG Committees - TradingView
Biotech veteran Robert Azelby joins Tango Therapeutics (TNGX) board as company advances vopimetostat - Stock Titan
Positive trial data lifts forecasts for Tango Therapeutics’ oncology program - S&P Global
Tango Therapeutics Appoints New Board Member - Intellectia AI
Tango Therapeutics Company Profile & Introduction - Moomoo
Tango Therapeutics Inc (TNGX) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):